Market Currents
Goldman Sachs upgrades Amgen (AMGN) to Neutral from Sell on the heels of the biotech concern's...
-
Friday, December 16, 2011, 7:07 AM ETGoldman Sachs upgrades Amgen (AMGN) to Neutral from Sell on the heels of the biotech concern's change in management. Analysts with the firm have been calling for a "new strategic direction" for AMGN for quite a while.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
